Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 14/20 | 0.71 |
| ▸ | THRB | P10828 | 14/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2786907 | 0.89 | THRB (0.67) | THRATHRBEPHX1EPHX2 | |
| SCHEMBL4426297 | 0.83 | THRB (1.00) | THRATHRB | |
| SCHEMBL5619110 | 0.79 | THRB (0.65) | THRATHRBHIF1A | |
| SCHEMBL4347525 | 0.79 | THRB (0.49) | THRATHRBHIF1A | |
| SCHEMBL4356852 | 0.78 | THRB (0.48) | THRATHRBEPHX1EPHX2HIF1A | |
| SCHEMBL4530357 | 0.77 | THRA (0.71) | THRATHRB | |
| SCHEMBL2787486 | 0.76 | THRB (0.64) | THRATHRB | |
| SCHEMBL4424982 | 0.73 | THRB (0.81) | THRATHRB | |
| SCHEMBL3785584 | 0.73 | THRB (0.59) | THRATHRBEPHX1EPHX2 | |
| SCHEMBL2787292 | 0.73 | THRB (0.71) | THRATHRBEPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557143-B2 | Thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-07 | — | — | US | claimed |
| US-8263659-B2 | Thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263659-B2 | Thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263659-B2 | Thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20100298276-A1 | THYROID RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2010-11-25 | — | — | US | disclosed |
| US-20100298276-A1 | THYROID RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2010-11-25 | — | — | US | disclosed |
| US-20100298276-A1 | THYROID RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2010-11-25 | — | — | US | disclosed |
| US-7557143-B2 | Thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557143-B2 | Thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557143-B2 | Thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-20050004184-A1 | Thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-06 | — | — | US | disclosed |
| WO-2004093799-A2 | THYROID RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298276-A1 | THYROID RECEPTOR LIGANDS | TSHR, THRA, THRB | THRA 2/4885THRB 3/4885KDM4E 3520/4885 |
| US-20050004184-A1 | Thyroid receptor ligands | TSHR, THRA, THRB | THRA 2/4885THRB 3/4885KDM4E 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.